

Sterile Vials Market is Expanding at a CAGR of 8.5% by 2035 | Fact.MR Report

The Sterile Vials Market Is Expected To Total USD 6.7 Billion In 2025, And Is Likely To Touch USD 15.1 Billion By 2035, Expanding At A CAGR Of 8.5%

ROCKVILLE, MD, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- The latest report on the [Sterile Vials Market](#), projecting significant growth driven by rising demand for biologics, vaccines, and advanced pharmaceutical packaging solutions. Valued at USD 6.7 billion in 2025, the global market is forecast to expand at a compound annual growth rate (CAGR) of 8.5%, reaching USD 15.1 billion by 2035. This robust expansion underscores the critical role of sterile vials in ensuring drug safety and efficacy amid growing chronic disease prevalence and global health challenges.



For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=5775

Market Outlook and Growth Projections:

The global sterile vials market is set for substantial growth from 2025 to 2035, fueled by increasing demand for biologics, vaccines, and sterile packaging solutions. The market is expected to grow from USD 6.7 billion in 2025 to USD 15.1 billion by 2035, registering a steady CAGR of 8.5%. Key drivers include the rising prevalence of chronic and infectious diseases, with 37.9 million people living with HIV in 2018 (UNAIDS) and ongoing vaccine development needs, as seen during the COVID-19 pandemic. Advancements in vial manufacturing, such as ready-to-use (RTU) vials and automation, further support market expansion, offering significant opportunities

for manufacturers and suppliers.

Key Drivers Fueling Market Demand:

Several factors are propelling market growth. The increasing global demand for injectable drugs, particularly biologics and vaccines, drives the need for sterile vials, with the pharmaceutical industry valued at USD 1.3 trillion in the U.S. alone (Select USA). The rise in chronic diseases, such as diabetes and cardiovascular disorders, and infectious diseases necessitates robust sterile packaging to ensure drug integrity. Technological advancements, including hydrogen peroxide vapor sterilization and electron beam irradiation, enhance vial quality and reduce contamination risks. The growing adoption of RTU vials, which streamline manufacturing by eliminating in-house sterilization, and the expansion of biologics and biosimilars markets, with increasing FDA approvals, further boost demand.

Challenges and Restraints in the Sector:

Despite its strong outlook, the market faces challenges. High laboratory expenses during production, averaging USD 10,000–50,000 per batch, and additional costs for storage and transportation limit adoption, particularly in developing regions. Stringent regulatory requirements from the FDA and EMA, such as material compatibility and particulate control, increase compliance costs. Limitations on plastic vial usage due to environmental regulations and concerns over extractables and leachables pose further hurdles. Volatility in raw material prices, especially for pharmaceutical-grade glass, and supply chain disruptions also restrain growth.

Segment-Wise Insights and Dominant Trends:

The report provides detailed segmentation analysis, identifying sterile empty vials, including evacuated, nitrogen-filled, and air-filled vials, as the leading product segment, expected to capture the majority of demand due to their versatility in clinical and biopharmaceutical applications. By volume, 2 ml to 5 ml sterile vials are projected to see elevated demand, driven by their widespread use in vaccine and biologic packaging. Glass sterile vials dominate the material segment due to their non-reactive nature and compliance with environmental regulations, while plastic vials grow due to cost-effectiveness. Clinical labs lead as end users, followed by biopharmaceutical companies and compounding labs.

Buy Report – Instant Access: <https://www.factmr.com/checkout/5775>

Regional Outlook and Growth Hotspots:

North America holds the largest market share, contributing significantly to global revenue in 2024, driven by advanced clinical labs, a robust biopharmaceutical sector, and high demand from the U.S., which accounted for USD 558 billion in biopharmaceutical revenue in 2015 (Select

USA). Europe follows, with Germany leading due to its 500+ pharmaceutical companies and projected sales of USD 48 billion by 2031 (European Commission). Asia-Pacific is the fastest-growing region, with China's pharmaceutical market reaching USD 154 billion in 2020 (Select USA) and India's biotechnology sector projected at USD 150 billion by 2025 (Invest India). Latin America and the Middle East and Africa (MEA) are emerging markets, supported by healthcare infrastructure growth and biosimilar adoption. Asia-Pacific's large population and rising chronic disease prevalence make it a key growth engine.

Recent Developments:

The market has seen significant innovations. In October 2020, ALK Life Science Solutions partnered with UPPI LLC to supply high-quality glass vials for radiopharmaceuticals. In February 2020, West Pharmaceutical Services launched AccelTRA Select EU configurations for ready-to-use and ready-to-sterilize vials. In May 2020, Pfizer and Corning Incorporated signed a long-term supply agreement for Corning Valor Glass. Posts on X highlight advancements in sterilization technologies and RTU vial adoption, reflecting the market's shift toward efficiency and contamination-free solutions.

Key Players Insights:

Leading players are driving innovation through product diversification and strategic partnerships. Key companies include Adelphi Healthcare Packaging, APG Europe, Bormioli Pharma S.p.a., Corning Incorporated, Dalton Pharma Services, DWK Life Sciences GmbH, Gerresheimer AG, Nipro Corporation, O.Berk Company, Pacific Vial, Piramal Glass, Schott AG, SDG Pharma, Shandong Pharmaceutical Glass Co. Ltd., SiO2 Materials Science, Stevanato Group, Thermo Fisher Scientific, Inc., and West Pharmaceutical Services, Inc. Recent moves include Dalton Pharma Services' launch of clinical sterile vials and Nipro Corporation's customizable vial range. These companies are pursuing acquisitions, R&D, and expansion into emerging markets to meet growing demand, with strong growth projected through 2035.

Competitive Landscape:

The market features a competitive ecosystem with key players focusing on innovation and market expansion. Companies profiled include Adelphi Healthcare Packaging, Corning Incorporated, Gerresheimer AG, Schott AG, and West Pharmaceutical Services, Inc., among others. The report includes a detailed competition dashboard, benchmarking, and market share analysis, highlighting strategies such as product launches, mergers, and technological advancements. As demand for biologics and vaccines grows, these players are well-positioned to capitalize on opportunities in sterile packaging.

Check out More Related Studies Published by Fact.MR Research:

[Sterile Medical Packaging Market](#) is anticipated to reach US\$ 44.22 Billion in 2023 & further

expand at a CAGR of 7% to reach US\$ 86.99 Billion by 2033-end

[Sterile injectable drug market](#) size is estimated at US\$ 611.7 Billion in 2024 & is forecasted to increase at a CAGR of 7.6% to reach US\$ 1,277.1 Billion by 2034

S. N. Jha

Fact.MR

+1 628-251-1583

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/843222245>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.